|Articles|December 13, 2013

New Drug Combo Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer

Adding dasatinib to standard antihormone therapy letrozole significantly improved the progression-free survival of women with hormone receptor–positive, HER2-negative metastatic breast cancer, according to the results of a small phase II study. Investigator Dev Paul, DO, PhD, of Rocky Mountain Cancer Centers cautioned that more information is needed to determine which patients will benefit from the addition of dasatinib.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

New Drug Combo Delayed Disease Progression for Subgroup of Women With Metastatic Breast Cancer

Newsletter

Related Content

Collaboration May Expedite ctDNA Use and Inform Adjuvant Rectal Cancer Care

Exploring the Interplay Between Surgery and Radiation in Gastric Cancer

Zanidatamab Combinations Boost Survival in Advanced/Metastatic GEA

Atezolizumab Combo May Improve Outcomes Vs TACE in Intermediate-Stage HCC

Lirafugratinib Displays Antitumor Activity in Advanced FGFR2-Mutated CCA

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Washington State Medical Oncology Society

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Wyoming and Montana

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | New Mexico

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | North Carolina

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

21st Annual New York Lung Cancers Symposium®

9th Annual School of Nursing Oncology™

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Optimizing Multidisciplinary Care in TGCT

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Diagnosis and Management of TGCT

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(Pharmacist Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

“D” Is for Diagnosis: Decoding a Difficult Thoracic Malignancy – Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arizona

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes